Tanaka, Minoru
Roberts, Justin M
Seo, Hyuk-Soo
Souza, Amanda
Paulk, Joshiawa
Scott, Thomas G
DeAngelo, Stephen L
Dhe-Paganon, Sirano
Bradner, James E
Article History
Received: 23 December 2015
Accepted: 2 August 2016
First Online: 24 October 2016
Competing interests
: M.T. is a visiting scientist from Mitsubishi Tanabe Pharma Corporation and is supported by the company for nonresearch funds. J.E.B. is a founder of Tensha Therapeutics, a biotechnology company that develops drug-like derivatives of JQ1 as investigational cancer therapies. Dana-Farber Cancer Institute and M.T., J.M.R. and J.E.B. have filed patent applications (62/259,797, 62/261,703 and 62/338,968) that include MT1 and the analogs described in this manuscript. J.E.B. is an employee of the Novartis Institutes of BioMedical Research (effective 1 January 2016).